Literature DB >> 8215286

Multicenter comparison of in vitro activities of FK-037, cefepime, ceftriaxone, ceftazidime, and cefuroxime.

J A Washington1, R N Jones, E H Gerlach, P R Murray, S D Allen, C C Knapp.   

Abstract

In a multicenter study, the MICs of FK-037 for 90% of the strains tested (MIC90s) were < or = 1 microgram/ml for members of the family Enterobacteriaceae other than Citrobacter freundii, Enterobacter spp., and Serratia marcescens. Activity against Pseudomonas aeruginosa was variable, with a MIC50 and a MIC90 of 4 and 32 micrograms/ml, respectively. Relative to cefepime, however, FK-037 was less active against ceftazidime-resistant isolates of Enterobacter cloacae. The MIC90 of FK-037 for methicillin-resistant staphylococci was > 16 micrograms/ml.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8215286      PMCID： PMC188045          DOI： 10.1128/AAC.37.8.1696

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  6 in total

1.  Activity of cefepime, ceftazidime, and ceftizoxime against mutants of Enterobacteriaceae and Pseudomonas aeruginosa derepressed for class I beta-lactamase.

Authors:  C C Knapp; J A Washington
Journal:  J Antimicrob Chemother       Date:  1989-12       Impact factor: 5.790

2.  Activity of cefepime (BMY-28142) and cefpirome (HR 810) against gram-negative bacilli resistant to cefotaxime or ceftazidime.

Authors:  R N Jones; P C Fuchs
Journal:  J Antimicrob Chemother       Date:  1989-01       Impact factor: 5.790

3.  In vitro activity and beta-lactamase stability of FK-037, a parenteral cephalosporin.

Authors:  H C Neu; N X Chin; H B Huang
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191

4.  In vitro and in vivo antibacterial activities of FK037, a novel parenteral broad-spectrum cephalosporin.

Authors:  K P Fu; B D Foleno; S C Lafredo; J M LoCoco; D M Isaacson
Journal:  Antimicrob Agents Chemother       Date:  1993-02       Impact factor: 5.191

5.  Activity of cefepime against ceftazidime- and cefotaxime-resistant gram-negative bacteria and its relationship to beta-lactamase levels.

Authors:  J Fung-Tomc; T J Dougherty; F J DeOrio; V Simich-Jacobson; R E Kessler
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

6.  In vitro activity of FK037, a new parenteral cephalosporin, against anaerobic bacteria.

Authors:  N Kato; H Kato; Y Tanaka; K Bando; K Watanabe; K Ueno
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191
  6 in total
  12 in total

1.  Cefepime versus ceftriaxone for empiric treatment of hospitalized patients with community-acquired pneumonia. The Cefepime Study Group.

Authors:  M Zervos; M Nelson
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

2.  Relationship of Pulmonary Outcomes, Microbiology, and Serum Antibiotic Concentrations in Cystic Fibrosis Patients.

Authors:  Andrea Hahn; Caroline Jensen; Hani Fanous; Hollis Chaney; Iman Sami; Geovanny F Perez; Stan Louie; Anastassios C Koumbourlis; James E Bost; John N van den Anker
Journal:  J Pediatr Pharmacol Ther       Date:  2018 Sep-Oct

3.  Multicentre comparative study on the antibacterial activity of FK-037, a new parenteral cephalosporin.

Authors:  J Martínez-Beltrán; R Cantón; J Liñares; J García de Lomas; C Gimeno; F Tubau; F Baquero
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-03       Impact factor: 3.267

4.  Decision analysis modelling of costs and outcomes following cefepime monotherapy in Canada.

Authors:  M T Halpern; R E Brown; M Drolet; S V Sorensen; L A Mandell
Journal:  Can J Infect Dis       Date:  1997-01

5.  Effectiveness of short-course therapy (5 days) with cefuroxime axetil in treatment of secondary bacterial infections of acute bronchitis.

Authors:  D Henry; G E Ruoff; J Rhudy; A Puopolo; M Drehobl; J Schoenberger; G Giguere; J J Collins
Journal:  Antimicrob Agents Chemother       Date:  1995-11       Impact factor: 5.191

6.  Ceftriaxone/Amikacin vs Ceftazidime/Amikacin as Empirical Therapy for Fever in Patients with Haematological Malignancy and Severe Granulocytopenia: Clinical and Economic Outcomes.

Authors:  F Rossini; P Pioltelli; S Bolis; L Borin; I Casaroli; E Lanzi; P Maffè; M Parma; P Tripputi; E M Pogliani
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

Review 7.  Cefepime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  L B Barradell; H M Bryson
Journal:  Drugs       Date:  1994-03       Impact factor: 9.546

Review 8.  Cefuroxime axetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  C M Perry; R N Brogden
Journal:  Drugs       Date:  1996-07       Impact factor: 9.546

9.  Activity of the fourth generation cephalosporin FK-037 against methicillin-resistant Staphylococcus aureus under conditions maximizing PBP2' production.

Authors:  J M Hamilton-Miller
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-12       Impact factor: 3.267

10.  Three-times-weekly, post-dialysis cefepime therapy in patients on maintenance hemodialysis: a retrospective study.

Authors:  Eric Descombes; Filipe Martins; Ould Maouloud Hemett; Veronique Erard; Christian Chuard
Journal:  BMC Pharmacol Toxicol       Date:  2016-02-04       Impact factor: 2.483
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.